Lisa Argnani
Overview
Explore the profile of Lisa Argnani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Argnani L, Casadei B, Zinzani P
Blood Cancer J
. 2025 Mar;
15(1):33.
PMID: 40055342
No abstract available.
2.
Pellegrini C, Casadei B, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al.
Ann Hematol
. 2025 Mar;
PMID: 40025210
Immune checkpoint inhibitors (CPIs) emerged as an effective and safe therapeutic option for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many patients lose their response to CPIs. To...
3.
Casadei B, Argnani L, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al.
Blood Adv
. 2025 Feb;
PMID: 39993241
No abstract available.
4.
Di Staso R, Casadei B, Locke F, Jain M, Voorhees T, Kittai A, et al.
Blood Cancer J
. 2024 Nov;
14(1):197.
PMID: 39511146
No abstract available.
5.
Mazzoni C, Argnani L, Casadei B, Broccoli A, Gabrielli G, Fabbri N, et al.
Eur J Haematol
. 2024 Sep;
114(1):70-78.
PMID: 39295142
First-line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional...
6.
Casadei B, Conti G, Barone M, Turroni S, Guadagnuolo S, Broccoli A, et al.
Hematol Oncol
. 2024 Aug;
42(5):e3301.
PMID: 39104142
Biomarkers for immune checkpoint inhibitors (ICIs) response and resistance include PD-L1 expression and other environmental factors, among which the gut microbiome (GM) is gaining increasing interest especially in lymphomas. To...
7.
Di Staso R, Casadei B, Gentilini M, Guadagnuolo S, Pellegrini C, Broccoli A, et al.
Ann Hematol
. 2024 May;
103(7):2499-2509.
PMID: 38695872
Poor literature report actual and detailed costs of chimeric antigen receptor (CAR) T-cell pathway in a real-life setting. We retrospectively collect data for all patients with relapsed/refractory aggressive large B-cell...
8.
Broccoli A, Argnani L, Gugliotta G, Pellegrini C, Casadei B, Bagnato G, et al.
Oncologist
. 2024 Feb;
29(6):e789-e795.
PMID: 38339976
Introduction: Intensive treatment approaches are required for adult patients with Burkitt lymphoma (BL), although an univocal standard of care still does not exist. The use of frontline autologous stem cells...
9.
Bagnato G, Stefoni V, Broccoli A, Argnani L, Pellegrini C, Casadei B, et al.
Mediterr J Hematol Infect Dis
. 2024 Jan;
16(1):e2024004.
PMID: 38223480
We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosylate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zest homolog 1 and 2,...
10.
Giladi O, Bagnato G, Gentilini M, Shimony S, Pasvolsky O, Berger T, et al.
Ann Hematol
. 2023 Nov;
103(3):803-811.
PMID: 37950052
The COVID-19 pandemic posed a major challenge in cancer care worldwide which might have an impact on the management of diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective study...